Atherosclerosis
Volume 210, Issue 2 , Pages 337-343 , June 2010

The genetics of statin-induced myopathy

  • Abhijit Ghatak

      Affiliations

    • Department of Internal Medicine, University of Connecticut, Farmington, CT 06032, USA
    • ,
  • Osman Faheem

      Affiliations

    • Division of Cardiology, The Henry Low Heart Centre, Hartford Hospital, 80 Seymour Street, Hartford, CT 06102, USA
    • ,
  • Paul D. Thompson

      Affiliations

    • Division of Cardiology, The Henry Low Heart Centre, Hartford Hospital, 80 Seymour Street, Hartford, CT 06102, USA
    • Corresponding Author InformationCorresponding author at: Division of Cardiology, Hartford Hospital, 80 Seymour Street, PO Box 5037, Hartford, CT 06102-5037, USA. Tel.: +1 860 545 2880; fax: +1 860 545 2882.

Received 17 October 2009 ,Revised 20 November 2009 ,Accepted 20 November 2009.

References 

  1. Shepherd J. Who should receive a statin these days? Lessons from recent clinical trials. J Intern Med. 2006;260:305–319
  2. Thompson PD, Clarkson PM, Rosenson RS. An assessment of statin safety by muscle experts. Am J Cardiol. 2006;97:69C–76C
  3. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA. 2003;289:1681–1690
  4. Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients—the PRIMO study. Cardiovasc Drugs Ther. 2005;19:403–414
  5. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med. 2002;346:539–540
  6. Rosenson RS. Current overview of statin-induced myopathy. Am J Med. 2004;116:408–416
  7. Venero CV, Thompson PD. Managing statin myopathy. Endocrinol Metab Clin North Am. 2009;38:121–136
  8. Draeger A, Monastyrskaya K, Mohaupt M, et al. Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia. J Pathol. 2006;210:94–102
  9. Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol. 2007;49:2231–2237
  10. Phillips PS, Haas RH. Statin myopathy as a metabolic muscle disease. Expert Rev Cardiovasc Ther. 2008;6:971–978
  11. Yokoyama M, Seo T, Park T, et al. Effects of lipoprotein lipase and statins on cholesterol uptake into heart and skeletal muscle. J Lipid Res. 2007;48:646–655
  12. Paiva H, Thelen KM, Van Coster R, et al. High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial. Clin Pharmacol Ther. 2005;78:60–68
  13. Urso ML, Clarkson PM, Hittel D, Hoffman EP, Thompson PD. Changes in ubiquitin proteasome pathway gene expression in skeletal muscle with exercise and statins. Arterioscler Thromb Vasc Biol. 2005;25:2560–2566
  14. Guis S, Figarella-Branger D, Mattei JP, et al. In vivo and in vitro characterization of skeletal muscle metabolism in patients with statin-induced adverse effects. Arthritis Rheum. 2006;55:551–557
  15. Moosmann B, Behl C. Selenoprotein synthesis and side-effects of statins. Lancet. 2004;363:892–894
  16. Vladutiu GD, Simmons Z, Isackson PJ, et al. Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve. 2006;34:153–162
  17. Link E, Parish S, Armitage J, et al. SLCO1B1 variants and statin-induced myopathy—a genomewide study. N Engl J Med. 2008;359:789–799
  18. Lennernas H, Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin Pharmacokinet. 1997;32:403–425
  19. McClure DL, Valuck RJ, Glanz M, Murphy JR, Hokanson JE. Statin and statin-fibrate use was significantly associated with increased myositis risk in a managed care population. J Clin Epidemiol. 2007;60:812–818
  20. Jacobson TA. Statin safety: lessons from new drug applications for marketed statins. Am J Cardiol. 2006;97:44C–51C
  21. Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther. 2007;82:726–733
  22. Konig J, Seithel A, Gradhand U, Fromm MF. Pharmacogenomics of human OATP transporters. Naunyn Schmiedebergs Arch Pharmacol. 2006;372:432–443
  23. Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics. 2006;16:873–879
  24. Chen C, Stock JL, Liu X, et al. Utility of a novel Oatp1b2 knockout mouse model for evaluating the role of Oatp1b2 in the hepatic uptake of model compounds. Drug Metab Dispos. 2008;36:1840–1845
  25. Niemi M, Pasanen MK, Neuvonen PJ. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin Pharmacol Ther. 2006;80:356–366
  26. Niemi M, Schaeffeler E, Lang T, et al. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics. 2004;14:429–440
  27. Morimoto K, Oishi T, Ueda S, et al. A novel variant allele of OATP-C (SLCO1B1) found in a Japanese patient with pravastatin-induced myopathy. Drug Metab Pharmacokinet. 2004;19:453–455
  28. Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M, Chiba K. Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics. 2005;15:513–522
  29. Voora D, Shah SH, Spasojevic I, et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol. 2009;54:1609–1616
  30. Butler MA, Lang NP, Young JF, et al. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics. 1992;2:116–127
  31. Williams D, Feely J. Pharmacokinetic–pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet. 2002;41:343–370
  32. Nordin C, Dahl ML, Eriksson M, Sjoberg S. Is the cholesterol-lowering effect of simvastatin influenced by CYP2D6 polymorphism?. Lancet. 1997;350:29–30
  33. Marez D, Legrand M, Sabbagh N, et al. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics. 1997;7:193–202
  34. Johansson I, Lundqvist E, Bertilsson L, et al. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA. 1993;90:11825–11829
  35. Dahl ML, Johansson I, Bertilsson L, Ingelman-Sundberg M, Sjoqvist F. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther. 1995;274:516–520
  36. Mulder AB, van Lijf HJ, Bon MA, et al. Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin. Clin Pharmacol Ther. 2001;70:546–551
  37. Kim K, Johnson JA, Derendorf H. Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms. J Clin Pharmacol. 2004;44:1083–1105
  38. Zuccaro P, Mombelli G, Calabresi L, et al. Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin. Pharmacol Res. 2007;55:310–317
  39. Pasternak RC, Smith SC, Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins(1) (2). J Am Coll Cardiol. 2002;40:567–572
  40. Bullen WW, Miller RA, Hayes RN. Development and validation of a high-performance liquid chromatography tandem mass spectrometry assay for atorvastatin, ortho-hydroxy atorvastatin, and para-hydroxy atorvastatin in human, dog, and rat plasma. J Am Soc Mass Spectrom. 1999;10:55–66
  41. Wilke RA, Moore JH, Burmester JK. Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage. Pharmacogenet Genomics. 2005;15:415–421
  42. Ishikawa C, Ozaki H, Nakajima T, et al. A frameshift variant of CYP2C8 was identified in a patient who suffered from rhabdomyolysis after administration of cerivastatin. J Hum Genet. 2004;49:582–585
  43. Transon C, Leemann T, Dayer P. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur J Clin Pharmacol. 1996;50:209–215
  44. Carswell CI, Plosker GL, Jarvis B. Rosuvastatin. Drugs. 2002;62:2075–2085
  45. Bolego C, Poli A, Cignarella A, Catapano AL, Paoletti R. Novel statins: pharmacological and clinical results. Cardiovasc Drugs Ther. 2002;16:251–257
  46. Guijarro C, Blanco-Colio LM, Ortego M, et al. 3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res. 1998;83:490–500
  47. Ruano G, Thompson PD, Windemuth A, et al. Physiogenomic analysis links serum creatine kinase activities during statin therapy to vascular smooth muscle homeostasis. Pharmacogenomics. 2005;6:865–872
  48. Heydemann A, McNally E. NO more muscle fatigue. J Clin Invest. 2009;119:448–450
  49. Koeppe C, Schneider C, Thieme K, et al. The influence of the 5-HT3 receptor antagonist tropisetron on pain in fibromyalgia: a functional magnetic resonance imaging pilot study. Scand J Rheumatol Suppl. 2004;24–27
  50. Ruano G, Thompson PD, Windemuth A, et al. Physiogenomic association of statin-related myalgia to serotonin receptors. Muscle Nerve. 2007;36:329–335
  51. Wolfe GI, Baker NS, Haller RG, Burns DK, Barohn RJ. McArdle's disease presenting with asymmetric, late-onset arm weakness. Muscle Nerve. 2000;23:641–645
  52. Lorenzoni PJ, Silvado CE, Scola RH, Luvizotto M, Werneck LC. McArdle disease with rhabdomyolysis induced by rosuvastatin: case report. Arq Neuropsiquiatr. 2007;65:834–837
  53. Livingstone C, Al Riyami S, Wilkins P, Ferns GA. McArdle's disease diagnosed following statin-induced myositis. Ann Clin Biochem. 2004;41:338–340
  54. Barth JH, Brownjohn AM, Jamieson DR. The case of stainless statins. Ann Clin Biochem. 2003;40:576–577
  55. Voermans NC, Lammens M, Wevers RA, Hermus AR, van Engelen BG. Statin-disclosed acid maltase deficiency. J Intern Med. 2005;258:196–197
  56. Corti S, Bordoni A, Ronchi D, et al. Clinical features and new molecular findings in Carnitine Palmitoyltransferase II (CPT II) deficiency. J Neurol Sci. 2008;266:97–103
  57. Bonnefont JP, Demaugre F, Prip-Buus C, et al. Carnitine palmitoyltransferase deficiencies. Mol Genet Metab. 1999;68:424–440
  58. Harrison's principles of internal medicine. New York: McGraw-Hill; 2009;
  59. Bonnefont JP, Djouadi F, Prip-Buus C, et al. Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspects. Mol Aspects Med. 2004;25:495–520
  60. Bhuiyan J, Seccombe DW. The effects of 3-hydroxy-3-methylglutaryl-CoA reductase inhibition on tissue levels of carnitine and carnitine acyltransferase activity in the rabbit. Lipids. 1996;31:867–870
  61. Verzijl HT, van Engelen BG, Luyten JA, et al. Genetic characteristics of myoadenylate deaminase deficiency. Ann Neurol. 1998;44:140–143
  62. Morisaki T, Gross M, Morisaki H, et al. Molecular basis of AMP deaminase deficiency in skeletal muscle. Proc Natl Acad Sci USA. 1992;89:6457–6461
  63. Tarnopolsky MA, Parise G, Gibala MJ, Graham TE, Rush JW. Myoadenylate deaminase deficiency does not affect muscle anaplerosis during exhaustive exercise in humans. J Physiol. 2001;533:881–889
  64. Goto Y, Nonaka I, Horai S. A mutation in the tRNA(Leu)(UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies. Nature. 1990;348:651–653
  65. Goto Y, Nonaka I, Horai S. A new mtDNA mutation associated with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS). Biochim Biophys Acta. 1991;1097:238–240
  66. Nishino I, Komatsu M, Kodama S, et al. The 3260 mutation in mitochondrial DNA can cause mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes (MELAS). Muscle Nerve. 1996;19:1603–1604
  67. Thomas JE, Lee N, Thompson PD. Statins provoking MELAS syndrome. A case report. Eur Neurol. 2007;57:232–235
  68. Chariot P, Abadia R, Agnus D, et al. Simvastatin-induced rhabdomyolysis followed by a MELAS syndrome. Am J Med. 1993;94:109–110
  69. Tay SK, DiMauro S, Pang AY, Lai PS, Yap HK. Myotoxicity of lipid-lowering agents in a teenager with MELAS mutation. Pediatr Neurol. 2008;39:426–428
  70. Blake JC, Taanman JW, Morris AM, et al. Mitochondrial DNA depletion syndrome is expressed in amniotic fluid cell cultures. Am J Pathol. 1999;155:67–70
  71. Schick BA, Laaksonen R, Frohlich JJ, et al. Decreased skeletal muscle mitochondrial DNA in patients treated with high-dose simvastatin. Clin Pharmacol Ther. 2007;81:650–653
  72. Phillips PS, Haas RH, Bannykh S, et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med. 2002;137:581–585
  73. Vladitu G, Isackson P, Wortmann R. Metabolic muscle disorders and cholesterol-lowering drugs. In: American College of Rheumatology 2004 Meeting (Abstract 1784). 2004;[Ref Type: Abstract]
  74. Quinzii C, Naini A, Salviati L, et al. A mutation in para-hydroxybenzoate-polyprenyl transferase (COQ2) causes primary coenzyme Q10 deficiency. Am J Hum Genet. 2006;78:345–349
  75. Oh J, Ban MR, Miskie BA, Pollex RL, Hegele RA. Genetic determinants of statin intolerance. Lipids Health Dis. 2007;6:7
  76. Sailler L, Pereira C, Bagheri A, et al. Increased exposure to statins in patients developing chronic muscle diseases: a 2-year retrospective study. Ann Rheum Dis. 2008;67:614–619
  77. Nakahara K, Yada T, Kuriyama M, Osame M. Cytosolic Ca2+ increase and cell damage in L6 rat myoblasts by HMG-CoA reductase inhibitors. Biochem Biophys Res Commun. 1994;202:1579–1585
  78. Inoue R, Tanabe M, Kono K, et al. Ca2+-releasing effect of cerivastatin on the sarcoplasmic reticulum of mouse and rat skeletal muscle fibers. J Pharmacol Sci. 2003;93:279–288
  79. Ikemoto T, Endo M. Properties of Ca(2+) release induced by clofibric acid from the sarcoplasmic reticulum of mouse skeletal muscle fibres. Br J Pharmacol. 2001;134:719–728
  80. Gray DF, Bundgaard H, Hansen PS, et al. HMG CoA reductase inhibition reduces sarcolemmal Na(+)-K(+) pump density. Cardiovasc Res. 2000;47:329–335
  81. Baker SK, Tarnopolsky MA. Statin myopathies: pathophysiologic and clinical perspectives. Clin Invest Med. 2001;24:258–272
  82. Mosieniak G, Figiel I, Kaminska B. Cyclosporin A, an immunosuppressive drug, induces programmed cell death in rat C6 glioma cells by a mechanism that involves the AP-1 transcription factor. J Neurochem. 1997;68:1142–1149
  83. Kalow W, Britt BA, Chan FY. Epidemiology and inheritance of malignant hyperthermia. Int Anesthesiol Clin. 1979;17:119–139
  84. Gillard EF, Otsu K, Fujii J, et al. A substitution of cysteine for arginine 614 in the ryanodine receptor is potentially causative of human malignant hyperthermia. Genomics. 1991;11:751–755
  85. Monnier N, Procaccio V, Stieglitz P, Lunardi J. Malignant-hyperthermia susceptibility is associated with a mutation of the alpha 1-subunit of the human dihydropyridine-sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle. Am J Hum Genet. 1997;60:1316–1325
  86. Urwyler A, Deufel T, McCarthy T, West S. Guidelines for molecular genetic detection of susceptibility to malignant hyperthermia. Br J Anaesth. 2001;86:283–287
  87. Krivosic-Horber R, Depret T, Wagner JM, Maurage CA. Malignant hyperthermia susceptibility revealed by increased serum creatine kinase concentrations during statin treatment. Eur J Anaesthesiol. 2004;21:572–574
  88. Torbergsen T. A family with dominant hereditary myotonia, muscular hypertrophy, and increased muscular irritability, distinct from myotonia congenita thomsen. Acta Neurol Scand. 1975;51:225–232
  89. Burns RJ, Bretag AH, Blumbergs PC, Harbord MG. Benign familial disease with muscle mounding and rippling. J Neurol Neurosurg Psychiatry. 1994;57:344–347
  90. Kubisch C, Ketelsen UP, Goebel I, Omran H. Autosomal recessive rippling muscle disease with homozygous CAV3 mutations. Ann Neurol. 2005;57:303–304
  91. Ansevin CF, Agamanolis DP. Rippling muscles and myasthenia gravis with rippling muscles. Arch Neurol. 1996;53:197–199
  92. Minetti C, Sotgia F, Bruno C, et al. Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophy. Nat Genet. 1998;18:365–368
  93. Stephan DA, Hoffman EP. Physical mapping of the rippling muscle disease locus. Genomics. 1999;55:268–274
  94. Torbergsen T. Rippling muscle disease: a review. Muscle Nerve. 2002;(Suppl. 11):S103–S107
  95. Baker SK, Tarnopolsky MA. Sporadic rippling muscle disease unmasked by simvastatin. Muscle Nerve. 2006;34:478–481
  96. Grable-Esposito P, Katzberg HD, Greenberg SA, et al. Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve. 2009;

☆ No funding was received for this project.

PII: S0021-9150(09)00990-3

doi: 10.1016/j.atherosclerosis.2009.11.033

Atherosclerosis
Volume 210, Issue 2 , Pages 337-343 , June 2010

Article Tools